Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Inclusion Criteria: * JNCL as determined by a characteristic clinical presentation and confirmatory genetic evidence. * Able to walk 10 feet without assistance beyond that required due to vision impairment. * Subjects with local treating clinician (pediatrician or neurologist) willing to conduct the trial according to the protocol, good clinical practice, and applicable regulations. * Subjects with a parent/legal guardian willing to accompany them to all study visits, oversee study drug compliance, and monitor and report to local treating clinician/investigator and the URBC investigative personnel any signs of adversity. Exclusion Criteria: * Inability to tolerate oral administration of medications * Concomitant medical condition, which, in the opinion of the local treating clinician, the parent(s)/guardian, or the URBC study investigator would place the child at greater than acceptable risk from: 1) travel by plane or car to the URBC on four occasions over the course of 22 weeks, 2) exposure to mycophenolate mofetil at protocol defined dosages for periods up to 8 weeks. * Anticipated inability of the child (on the part of the investigator, parent/guardian, or URBC study personnel) to comply with the rigors of the protocol.. * Use of disallowed concomitant medications. * Administration of immunosuppressive medications * History of any prior exposure to mycophenolate mofetil * History of hypersensitivity to mycophenolate mofetil, or any other component of the product * Hist…